Category: Latest News
-

Vertex Shares Jump After Positive Phase 3 Kidney Drug Results
Vertex Pharmaceuticals (NASDAQ:VRTX) shares climbed about 6% to $488.52 in premarket trading Thursday after the company reported encouraging results from a late-stage clinical trial of its kidney disease treatment povetacicept and said it plans to pursue U.S. regulatory approval. The drug is being developed to treat IgA nephropathy and showed a 52% reduction in proteinuria—a…
-

Hims & Hers Shares Jump on Analyst Upgrades After Novo Nordisk Partnership
Hims & Hers Health (NYSE:HIMS) shares climbed about 10% on Tuesday, extending Monday’s sharp rally of nearly 49% after analysts upgraded the stock following the company’s newly announced partnership with Novo Nordisk (NYSE:NVO). The collaboration, unveiled Monday, enables Hims & Hers to offer commercially available doses of Ozempic and Wegovy—including a newly developed pill formulation—as…
-

Via Transportation Shares Slip After Short Seller Challenges Platform Narrative
Via Transportation (NYSE:VIA) shares dropped about 2% on Tuesday after short seller Bleecker Street Research published a report questioning the company’s positioning as a software platform. In the report, Bleecker Street argued that Via’s operations resemble those of a labor-intensive transit contractor rather than a technology-driven platform business. The firm said its review of more…
-

Ondas Shares Gain After $15.8M Israeli Demining Contract
Ondas Inc. (NASDAQ:ONDS) shares climbed about 4% on Tuesday after the company said its subsidiary, 4M Defense, secured a $15.8 million initial contract under a demining program in Israel. The order represents the first stage of a broader national land-clearing initiative valued at more than $30 million. Additional phases could add another $30 million in…
-

Novo Nordisk Shares Slide After FDA Issues Warning Letter
Novo Nordisk A/S (NYSE:NVO) shares declined 2.8% on Tuesday after the company disclosed it had received a warning letter from the U.S. Food and Drug Administration related to shortcomings in postmarketing adverse event reporting. The FDA issued the letter on March 5, 2026, following an inspection of Novo Nordisk Inc. conducted between January 13 and…
-

Stagwell Expands Share Buyback as AI Marketing Push Fuels Growth
Stagwell Inc. (NASDAQ:STGW) reported steady revenue growth and stronger profitability for 2025 while expanding its share repurchase program, highlighting the company’s confidence in its AI-driven marketing strategy. The global marketing and technology network said total revenue for the year ended Dec. 31, 2025, increased 2% to $2.91 billion, while net revenue rose 6% to $2.43…
-

HeartBeam Partners With Mount Sinai to Advance AI-Powered ECG Technology
HeartBeam (NASDAQ:BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai aimed at accelerating the development and clinical validation of next-generation artificial intelligence ECG algorithms. The partnership will combine HeartBeam’s patented ECG platform—which captures the heart’s electrical activity from three non-coplanar dimensions—with Mount Sinai’s clinical and artificial intelligence expertise to build…
-

bioAffinity Launches Large-Scale Clinical Study for Lung Cancer Detection Technology
bioAffinity Technologies (NASDAQ:BIAF) announced on March 10, 2026, the launch of a large longitudinal clinical study involving 2,000 patients to evaluate the performance of its CyPath® Lung technology for early detection of lung cancer in individuals at high risk who have indeterminate lung nodules. The trial will utilize FlowPath Lung, an investigational version of the…
-

NexGel Secures Regenerative Biomaterials Portfolio From Celularity in Landmark Transaction
NEXGEL, Inc. (NASDAQ:NXGL) has signed an asset purchase and exclusive licensing agreement with Celularity, Inc. to obtain rights to Celularity’s commercial-stage regenerative biomaterials portfolio, the companies announced. The products focus on applications including tendon repair, skin grafts and bone regeneration. The agreement, dated March 6, 2026, carries a total potential value of up to $35…
-

Optical Cable Reports Higher Q1 Sales Driven by Enterprise and Specialty Markets
Optical Cable Corporation (NASDAQ:OCC) reported its financial results for the first quarter of fiscal 2026, which ended January 31, 2026. The company posted consolidated net sales of $16.4 million for the quarter, representing a 4.4% increase from $15.7 million in the same period last year. Growth was supported by stronger demand across both OCC’s enterprise…